Multiple sclerosis — autoimmune demyelinating disease of the central nervous system

Key characteristics

MS is defined by inflammatory demyelination and neurodegeneration within the CNS. Lesions — areas of myelin loss and axonal injury — may be visible on magnetic resonance imaging (MRI) and are often scattered in space and time. Typical hallmarks include relapses (episodes of new or worsening neurological dysfunction) and varying degrees of recovery. Over time some people develop a steady accumulation of disability.

Common symptoms and clinical types

• Symptoms: visual problems (optic neuritis), weakness, numbness, spasticity, coordination and balance problems, bladder or bowel dysfunction, fatigue, pain and cognitive changes.
• Clinical courses: relapsing–remitting MS (most common at onset), secondary progressive MS (gradual worsening after an initial relapsing course), and primary progressive MS (steady progression from onset).

Causes and risk factors

The exact cause of MS remains unknown. It is generally regarded as an immune-mediated disease influenced by genetic susceptibility and environmental factors. Risk factors that are widely recognized include a family history of MS, female sex, lower vitamin D status and prior infection with certain viruses. Research indicates that aberrant immune responses target myelin-producing cells (oligodendrocytes) in the CNS, but precise triggers and mechanisms are under active study.

Diagnosis and investigation

Diagnosis is clinical and supported by tests showing lesions separated in space and time. MRI of the brain and spinal cord is the principal imaging tool to detect typical demyelinating plaques. Additional investigations may include lumbar puncture to detect inflammatory markers in cerebrospinal fluid, and evoked potentials to document slowed nerve conduction. Specialist neurological assessment integrates history, examination and investigation results to reach a diagnosis.

Treatment and management

Management has two complementary aims: altering the disease course and treating symptoms. Disease-modifying therapies (DMTs) reduce relapse frequency and slow progression for many people; these include injectable agents, oral medications and monoclonal antibodies. Acute relapses are often treated with short courses of corticosteroids. Supportive care addresses spasticity, pain, bladder dysfunction, mobility and fatigue, and rehabilitation (physiotherapy, occupational therapy, cognitive support) plays a central role in maintaining function and quality of life.

History, prognosis and public health

Multiple sclerosis was first described in detail in the 19th century and remains a major cause of neurological disability in young adults in many regions. Prognosis is variable: some people experience mild, intermittent symptoms for decades, while others accumulate disability more rapidly. Advances in imaging and therapy over recent decades have improved diagnostic accuracy and outcomes for many. For up-to-date overviews and clinical guidance, readers can consult authoritative resources such as disease summaries, immunology references at immune system resources, basic information on myelin at myelin-focused pages, and central nervous system overviews at CNS information.

Notable facts: MS is more common in temperate climates and typically begins in early adulthood. Research remains active on causes, biomarkers, neuroprotection and strategies for repair of myelin and axons. Early diagnosis and individualized therapy can substantially affect long-term outcomes.